This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by The European Recombinant LH Study Group, Search for Related Content PubMed PubMed Citation Articles by The European Recombinant LH Study Group,

Human Recombinant Luteinizing Hormone Is as Effective as, But Safer Than, Urinary Human Chorionic Gonadotropin in Inducing Final Follicular Maturation and Ovulation in in Vitro Fertilization Procedures: Results of a Multicenter Double-Blind Study¹

Geneva, Switzerland

Address correspondence and requests for reprints to: E. Loumaye, M.D., Ph.D., Serono International, 15 bis Chemin des Mines, CH-1202 Geneva, Switzerland.

Abstract

In a prospective, comparative, dose-finding study, the minimal effective dose of recombinant human LH (rhLH) required to induce final follicular maturation and early luteinization in patients undergoing in vitro fertilization and embryo transfer was determined. In addition, the efficacy and safety of rhLH were compared with urinary human CG (u-hCG). A total of 259 infertile women, aged 18–39 yr, were enrolled in the study. After pituitary desensitization using a GnRH agonist, rhFSH was administered for ovarian stimulation. Patients then received either rhLH or u-hCG to achieve final follicular maturation. The doses of rhLH administered were 5,000, 15,000, 30,000, or 15,000 + 10,000 IU (second injection administered 3 days after the first injection; 129 patients), and those of u-hCG were consistently 5,000 IU (121 patients). Ovum pick-up was performed 34–38 h after rhLH or u-hCG injection. After fertilization in vitro, up to three embryos were replaced in the uterine cavity. The numbers of oocytes retrieved after u-hCG or rhLH administration were not significantly different between the four different doses of rhLH, when compared with each corresponding u-hCG group, nor when compared with the pool of all u-hCG groups. Similarly, there were no statistically significant differences in: the number of oocytes retrieved per follicle with a diameter of over 10 mm on the day of u-hCG or rhLH administration; the number of patients with at least one oocyte retrieved; oocyte nuclear maturity; oocyte potential for fertilization; the number of embryos; the number of total, biochemical, and clinical pregnancies; and the embryo implantation rate. However, in many of these parameters, the lowest dose of rhLH seemed suboptimal when compared with the higher dose. In terms of safety, rhLH was well tolerated at a dose of up to 30,000 IU. Moderate ovarian hyperstimulation syndrome (OHSS) was reported in 12.4% of patients who received u-hCG and 12.0% of patients who received two injections of rhLH. No moderate or severe OHSS was reported in patients who received a single dose of rhLH up to 30,000 IU. The results show that a single dose of rhLH is effective in inducing final follicular maturation and early luteinization in in vitro fertilization and embryo transfer patients and is comparable with 5,000 IU u-hCG. A single dose of rhLH results in a highly significant reduction in OHSS compared with hCG. The dose of rhLH giving the highest efficacy to safety ratio was between 15,000 and 30,000 IU.

This article has been cited by other articles:

				S. R. Soares, R. Gomez, C. Simon, J. A. Garcia-Velasco, and A. Pellicer Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome Hum. Reprod. Update, April 2, 2008; (2008) dmn008v1. [Abstract] [Full Text] [PDF]

				M. A. Silvestre, J. Alfonso, E. Garcia-Mengual, I. Salvador, C. C. Duque, and I. Molina Effect of recombinant human follicle-stimulating hormone and luteinizing hormone on in vitro maturation of porcine oocytes evaluated by the subsequent in vitro development of embryos obtained by in vitro fertilization, intracytoplasmic sperm injection, or parthenogenetic activation J Anim Sci, May 1, 2007; 85(5): 1156 - 1160. [Abstract] [Full Text] [PDF]

				N. F. VLAHOS and O. GREGORIOU Prevention and Management of Ovarian Hyperstimulation Syndrome Ann. N.Y. Acad. Sci., December 1, 2006; 1092(1): 247 - 264. [Abstract] [Full Text] [PDF]

				U.-H. Stenman, A. Tiitinen, H. Alfthan, and L. Valmu The classification, functions and clinical use of different isoforms of HCG Hum. Reprod. Update, November 1, 2006; 12(6): 769 - 784. [Abstract] [Full Text] [PDF]

				N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization Endocr. Rev., April 1, 2006; 27(2): 170 - 207. [Abstract] [Full Text] [PDF]

				H. Al-Inany, M. A. Aboulghar, R. T. Mansour, and M. Proctor Recombinant versus urinary gonadotrophins for triggering ovulation in assisted conception Hum. Reprod., August 1, 2005; 20(8): 2061 - 2073. [Abstract] [Full Text] [PDF]

				S. D. McKenna, M. Pietropaolo, E. G. Tos, A. Clark, D. Fischer, D. Kagan, B. Bao, P. J. Chedrese, and S. Palmer Pharmacological Inhibition of Phosphodiesterase 4 Triggers Ovulation in Follicle-Stimulating Hormone-Primed Rats Endocrinology, January 1, 2005; 146(1): 208 - 214. [Abstract] [Full Text] [PDF]

				R Gomez, I Lima, C Simon, and A Pellicer Administration of low-dose LH induces ovulation and prevents vascular hyperpermeability and vascular endothelial growth factor expression in superovulated rats Reproduction, April 1, 2004; 127(4): 483 - 489. [Abstract] [Full Text] [PDF]

				N. G. M. Beckers, N. S. Macklon, M. J. Eijkemans, M. Ludwig, R. E. Felberbaum, K. Diedrich, S. Bustion, E. Loumaye, and B. C. J. M. Fauser Nonsupplemented Luteal Phase Characteristics after the Administration of Recombinant Human Chorionic Gonadotropin, Recombinant Luteinizing Hormone, or Gonadotropin-Releasing Hormone (GnRH) Agonist to Induce Final Oocyte Maturation in in Vitro Fertilization Patients after Ovarian Stimulation with Recombinant Follicle-Stimulating Hormone and GnRH Antagonist Cotreatment J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4186 - 4192. [Abstract] [Full Text] [PDF]

				H. Ando, K. Furugori, D. Shibata, T. Harata, Y. Murata, and S. Mizutani Dual renin-angiotensin blockade therapy in patients at high risk of early ovarian hyperstimulation syndrome receiving IVF and elective embryo cryopreservation: a case series Hum. Reprod., June 1, 2003; 18(6): 1219 - 1222. [Abstract] [Full Text] [PDF]

				M. Filicori, G.E. Cognigni, P. Pocognoli, C. Tabarelli, D. Spettoli, S. Taraborrelli, and W. Ciampaglia Modulation of folliculogenesis and steroidogenesis in women by graded menotrophin administration Hum. Reprod., August 1, 2002; 17(8): 2009 - 2015. [Abstract] [Full Text] [PDF]

				B. C. Fauser, D. de Jong, F. Olivennes, H. Wramsby, C. Tay, J. Itskovitz-Eldor, and H. G. van Hooren Endocrine Profiles after Triggering of Final Oocyte Maturation with GnRH Agonist after Cotreatment with the GnRH Antagonist Ganirelix during Ovarian Hyperstimulation for in Vitro Fertilization J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 709 - 715. [Abstract] [Full Text] [PDF]